During the last session, Inhibikase Therapeutics Inc (NASDAQ:IKT)’s traded shares were 0.34 million, with the beta value of the company hitting 1.16. At the end of the trading day, the stock’s price was $3.44, reflecting an intraday gain of 6.17% or $0.2. The 52-week high for the IKT share is $3.82, that puts it down -11.05 from that peak though still a striking 67.44% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $231.14M, and the average intraday trading volume over the past 10 days was 0.28 million shares, and the average trade volume was 542.29K shares over the past three months.
Inhibikase Therapeutics Inc (IKT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IKT has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Inhibikase Therapeutics Inc (NASDAQ:IKT) trade information
Inhibikase Therapeutics Inc (IKT) registered a 6.17% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.17% in intraday trading to $3.44, hitting a weekly high. The stock’s 5-day price performance is 4.88%, and it has moved by 42.15% in 30 days. Based on these gigs, the overall price performance for the year is 173.02%. The short interest in Inhibikase Therapeutics Inc (NASDAQ:IKT) is 0.19 million shares and it means that shorts have 0.17 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.5, which implies an increase of 47.08% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $8 respectively. As a result, IKT is trading at a discount of -132.56% off the target high and -45.35% off the low.
Inhibikase Therapeutics Inc (IKT) estimates and forecasts
Statistics show that Inhibikase Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Inhibikase Therapeutics Inc (IKT) shares have gone up 143.97% during the last six months, with a year-to-date growth rate more than the industry average at 72.83% against 16.40. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.31%. While earnings are projected to return 74.70% in 2024.
IKT Dividends
Inhibikase Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Inhibikase Therapeutics Inc (NASDAQ:IKT)’s Major holders
Inhibikase Therapeutics Inc insiders own 10.46% of total outstanding shares while institutional holders control 11.62%, with the float percentage being 12.98%.
Also, the Mutual Funds coming in first place with the largest holdings of Inhibikase Therapeutics Inc (IKT) shares are Fidelity Extended Market Index Fund and 360 Funds-Timber Point Global Tactical Allocation Fd . Data provided on Oct 31, 2024 indicates that Fidelity Extended Market Index Fund owns about 36.38 shares. This amounts to just over 0.05 percent of the company’s overall shares, with a $0.13 million market value. The same data shows that the other fund manager holds slightly less at 11.0, or about 0.02% of the stock, which is worth about $37840.0.
